Exploiting De Novo Serine Synthesis as a Metabolic Vulnerability to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma
M. Teisseire, U. Sahu, J. Parola, M.-C. Tsai, V. Vial, J. Durivault, R. Grepin, Y. Cormerais, G. Pages, I. Ben-Sahra, S. Giuliano
This study identifies serine synthesis as a metabolic vulnerability in sunitinib-resistant renal cell carcinoma, showing that inhibiting key enzymes enhances drug sensitivity.
bioRxiv · Mar 22, 2024 · PreprintCancer Biology